Dimerix LimitedASX: DXB

Dimerix Announces Board Chair Transition

Oct 18, 2026 at 5:30 PM EDT · Issued by Dimerix Limited via ASX

Filed with ASX · Oct 18, 2026 at 5:30 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/dimerix-announces-board-chair-transition

Release

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. Dimerix HQ 425 Smith St, Fitzroy 3065 Victoria, Australia T. 1300 813 321 E. [email protected] For Immediate Release DIMERIX ANNOUNCES BOARD CHAIR TRANSITION MELBOURNE, Australia, 19...

Dimerix Limited on 6ix

Earlier from Dimerix

DMX-200 First 100 Patients Complete Phase 3 Trial TreatmentOct 15
Dimerix at Canaccord Drug & Device and Ignite ConferencesOct 11
First Patient Reaches Four Years in DMX-200 Clinical ProgramOct 4
Notification regarding unquoted securities - DXBSep 28
Notification of 2026 Annual General Meeting DateSep 25

Later from Dimerix

2026 AGM Notice of Meeting, Letter of Access and Proxy FormOct 21
New Data Supports Biological Rationale for DMX-200 in FSGSOct 22
Dimerix Quarterly Activities Report and Appendix 4COct 28

All Dimerix news releases

Follow Dimerix into a list and get an email when it puts out news.

Follow Dimerix